Filing Flows

Filing Flows › Arbutus Biopharma (ABUS) › Next earnings date

Arbutus Biopharma (ABUS) earnings on Nov 16, 2026: what to expect

Arbutus Biopharma (ABUS) is expected to report earnings on Nov 16, 2026 (estimated), in 8 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.03 (1 estimate) on revenue of $1.4M, against −$0.06 and $741K a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 65% chance of beating next time.

Report dateNov 16, 2026 (estimated)
Days to go8
EPS estimate−$0.03
Revenue estimate$1.4M
Beat rate50%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Arbutus Biopharma: revenue lines, growth year over year, Q2 2026Arbutus Biopharma: revenue lines, growth year over year, Q2 2026Revenue-91%Collaborations and licenses-98%Non-cash royalty revenue-66%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.06 on revenue of $1.9M, against the analysts' −$0.03.

The last report

Arbutus Biopharma reported revenue of $1.0M for the second quarter 2026 (-91% Y/Y), net loss $5.1M: Revenue from collaborations and licenses $632K, Collaborations and licenses $202K, Non-cash royalty revenue $180K. How it makes money → · Every quarter →

Arbutus Biopharma: EPS against the estimate, last 4 reportsArbutus Biopharma: EPS against the estimate, last 4 reportsEstimateReported−$0.05−$0.06Nov 25−$0.06−$0.01Mar 26−$0.06$1.19May 26−$0.03−$0.04Aug 26
Latest (Aug 26): Estimate −$0.03, Reported −$0.04.

Arbutus Biopharma's latest quarter

Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.

Questions

When does ABUS report earnings?

Arbutus Biopharma is expected to report on Nov 16, 2026 (estimated).

What are analysts expecting from Arbutus Biopharma?

EPS of −$0.03 and revenue of $1.4M for the quarter.

Does Arbutus Biopharma usually beat earnings?

It beat the consensus EPS estimate in 50% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.